UK molecular diagnostics firm Lab21 has agreed to merge with French firm Novacyt, gaining a listing on the Alternext exchange in Paris and a presence in the cervical cancer screening market in the process.
UK molecular diagnostics firm Lab21 has agreed to merge with French firm Novacyt, gaining a listing on the Alternext exchange in Paris and a presence in the cervical cancer screening market in the process.
The stock-based reverse takeover will see Lab21’s shareholders receiving around 2.5 million Novacyt shares at an exchange ratio of 0.925...
Create an account to read this article
Already a subscriber?
The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.
Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.
Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.
